De-escalation in HPV-associated oropharyngeal cancer: lessons learned from the past? A critical viewpoint and proposal for future research
ConclusionsData obtained with de-intensified strategies should only serve to help select an appropriate experimental arm for a randomized controlled trial phase III comparison against cisplatin and 70 Gy of radiotherapy. Without a proper randomized trial, there remains the possibility of compromising survival, which raises ethical questions about conducting any de-escalation trial.
Source: European Archives of Oto-Rhino-Laryngology - Category: ENT & OMF Source Type: research
More News: Alcoholism | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | ENT & OMF | Erbitux | Genital Warts | Head and Neck Cancer | HNSCC | Human Papillomavirus (HPV) | Lessons | Medical Ethics | Oropharyngeal Cancer | Smokers | Squamous Cell Carcinoma | Study | Toxicology